Information  X 
Enter a valid email address

Ideagen PLC (IDEA)

  Print      Mail a friend

Friday 12 April, 2019

Ideagen PLC

Director Dealings

RNS Number : 0915W
Ideagen PLC
12 April 2019
 

Ideagen PLC

("Ideagen," "the Company" or the "Group'')

Director Dealing

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management Software to highly regulated industries, announces that Alan Carroll, a non-executive director, yesterday purchased 48 ordinary shares in the Company at a price of 150.5 pence each as a result of the automatic reinvestment of the Company's recent dividend by his nominated broker.

Following the purchase, Mr Carroll's beneficial interest has increased to 204,171 shares representing approximately 0.1% of the Company's issued ordinary share capital.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

Enquiries:

Ideagen plc

01629 699100

David Hornsby, Executive Chairman


Ben Dorks, Chief Executive


Graeme Spenceley, Finance Director




finnCap Limited

020 7220 0500

Henrik Persson/James Thompson (Nomad)


Alice Lane (ECM)


Canaccord Genuity

020 7523 8000

Simon Bridges


Ben Griffiths


Jack Haynes


About Ideagen plc

Ideagen is a UK-headquartered, global technology company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).

The Group provides software and services to organisations operating within highly regulated industries such as aviation, banking and finance and life science, with its main operational premises spread throughout the UK, EU, US, Middle East and SE Asia.

With an excellent portfolio of software products including Q-Pulse, Coruson, Pentana Audit and PleaseReview, Ideagen helps its clients reduce costs, improve operational efficiency, strengthen compliance and oversight and anticipate and manage every detail of risk.

Currently, more than 4,700 organisations use Ideagen's products including seven of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of the world's leading pharmaceutical firms.

Ideagen's diverse and varied customer base includes many well-known, global brands such as British Airways, Aggreko, BAE, Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank, Meggitt, Heineken, Johnson Matthey, Haeco Group and European Central Bank. As well as this, Ideagen counts 180 hospitals across the UK and US amongst its client base.

For further information please visit www.ideagen.com.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.            

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Alan Carroll

2.            

Reason for the Notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Ideagen plc

b)

LEI

213800KS1MLITOVNYC85

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 1p each

Identification code

GB00B0CM0C50

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

150.5p

   48

d)

Aggregated information:

·      Aggregated volume

·      Price

 

48 ordinary shares of 1p each purchased at 150.5p per share

e)

Date of the transaction

11 April 2019

f)

Place of the transaction

London Stock Exchange AIM market (XLON)

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHGGUPCCUPBGWP

a d v e r t i s e m e n t